sepsi
one
lead
caus
death
worldwid
incid
sever
sepsi
increas
mortal
rate
remain
significantli
high
despit
earli
care
manag
moreov
survivor
develop
longterm
function
disabl
cognit
impair
surviv
sepsi
campaign
global
initi
incept
earli
aim
improv
sepsi
diagnosi
treatment
order
enhanc
awar
sequela
decreas
high
mortal
rate
associ
collabor
mani
countri
europ
unit
state
surviv
sepsi
campaign
suggest
evidencebas
guidelin
bundl
recent
guidelin
recommend
acut
resuscit
septic
patient
administr
antibiot
support
organ
failur
yet
treatment
target
underli
mechan
sepsi
actual
avail
recombin
human
activ
protein
c
rhapc
eli
lilli
drug
specif
regist
sepsi
recent
withdrawn
market
follow
neg
result
prowessshock
studi
show
reduct
mortal
day
patient
septic
shock
gener
admit
sepsi
result
dysregul
host
respons
initi
insult
character
inflamm
mediat
tissu
damag
organ
failur
immun
suppress
state
respons
develop
secondari
infect
immun
respons
infect
initi
sens
microbi
structur
famili
receptor
collect
call
pattern
recognit
receptor
prr
welldescrib
famili
compris
tolllik
receptor
tlr
nucleotid
bind
oligomer
domain
nod
like
receptor
nlr
ctype
lectin
receptor
clr
dcsign
rigilik
receptor
rlr
rigi
intracytosol
dna
sensor
prr
express
innat
immun
cell
like
dendrit
cell
macrophag
bind
microbi
ligand
prr
promot
releas
mediat
among
cytokin
initi
regul
inflammatori
respons
necessari
elimin
invas
pathogen
coordin
develop
adapt
immun
respons
innat
immun
cell
also
trigger
damag
danger
associ
molecular
pattern
damp
known
alarmin
damp
endogen
compon
commonli
releas
injur
stress
cell
nucleic
acid
histon
uric
acid
crystal
atp
cytochrom
c
molecul
damp
primarili
sens
inflammasom
control
secret
concept
prr
sens
microbialassoci
molecular
pattern
mamp
discrimin
self
nonself
molecular
structur
propos
janeway
two
major
cornerston
discoveri
larg
confirm
janeway
concept
first
one
demonstr
essenti
antifung
role
toll
protein
drosophila
second
one
aros
posit
clone
link
lp
commonli
call
endotoxin
unrespons
phenotyp
strain
mice
missens
null
mutat
tolllik
receptor
gene
import
discoveri
role
dendrit
cell
central
regul
innat
adapt
immun
acknowledg
nobel
prize
physiolog
medicin
attribut
bruce
beutler
jule
hoffmann
discoveri
concern
activ
innat
immun
ralph
steinman
discoveri
dendrit
cell
role
adapt
immun
tolllik
receptor
belong
studi
famili
prr
due
central
role
host
defens
involv
number
patholog
process
includ
sepsi
tlr
type
transmembran
protein
compos
extracellular
leucinerich
repeat
lrr
domain
involv
ligand
recognit
transmembran
domain
tollinterleukin
receptor
tir
domain
involv
signal
function
human
tlr
function
mous
tlr
describ
one
involv
sens
distinct
microbi
product
tabl
express
cell
surfac
detect
lp
gramneg
bacteria
shuttl
late
endosom
induc
altern
signal
follow
lp
sens
heterodim
associ
either
possibl
sens
varieti
microbi
product
lipopeptid
lipoprotein
peptidoglycan
porin
glycosylphosphatidylinositol
gpi
anchor
glycoprotein
gramposit
bacteria
gramneg
bacteria
mycoplasma
mycobacteria
fungi
parasit
virus
sens
flagellin
bacteri
flagella
strateg
express
endosom
compart
recogn
microbi
nucleic
acid
doublestrand
rna
dsrna
singlestrand
rna
ssrna
unmethyl
cpg
motif
contain
dna
tabl
therefor
surpris
endosom
tlr
primarili
involv
host
defens
virus
wherea
mainli
involv
host
respons
bacteri
fungal
infect
tlr
cooper
molecul
recogn
microbi
ligand
exampl
requir
recognit
peptidoglycan
lipopeptid
respect
note
tlr
also
trigger
damp
releas
injur
stress
cell
infect
tabl
tlr
activ
enabl
pathogen
elimin
promot
bactericid
activ
leukocyt
matur
function
antigen
present
cell
thu
orchestr
develop
adapt
immun
respons
signal
pathway
result
tlr
trigger
engag
adaptor
recruit
tirtir
domain
interact
tabl
myeloid
differenti
primari
respons
gene
tir
domaincontain
adaptor
protein
tirap
also
known
mal
tir
domaincontain
adaptor
induc
interferon
ifn
trif
trif
relat
adaptor
molecul
tram
essenti
signal
tlr
except
involv
earli
nuclear
mitogenactiv
protein
kinas
mapk
activ
proinflammatori
gene
express
tirap
serv
bridg
recruit
trif
initi
ifn
regulatori
factor
late
activ
involv
product
type
ifn
ifninduc
gene
trif
recruit
cytoplasm
domain
late
endosom
tram
bridg
trif
fifth
tir
domaincontain
adaptor
steril
armadillomotif
contain
protein
sarm
act
neg
regul
signal
sarm
interact
trif
inhibit
induct
trifdepend
gene
signal
pathway
activ
downstream
tlr
redund
yet
engag
multipl
tlr
especi
trifdepend
tlr
synergist
effect
host
respons
intracellular
cross
talk
signal
pathway
may
also
occur
differ
famili
prr
involv
exampl
synerg
increas
cytokin
product
canon
noncanon
pathway
moreov
singl
mamp
detect
differ
prr
differenti
sens
primarili
depend
local
mamp
inde
flagellin
sens
express
cell
surfac
also
known
ipaf
inflammasom
local
cytoplasm
similarli
peptidoglycan
stimul
membran
intracytosol
cell
activ
interestingli
cpg
noncpg
oligodeoxynucleotid
directli
stimul
polar
tcell
mechan
possibl
intracellular
dna
sensor
recent
hagan
et
al
kayagaki
et
al
demonstr
noncanon
recognit
intracellular
lp
uncharacter
receptor
unconvent
mode
lp
sens
activ
secret
sensit
mice
endotox
shock
observ
indic
host
evolv
differ
strategi
sens
invad
microorgan
ideal
possibl
interact
character
andor
anticip
effect
treatment
applic
predict
andor
translat
mandat
care
plan
experi
repres
reallif
condit
detail
knowledg
compound
mode
action
obvious
redund
microbi
sens
pathway
taken
consider
develop
appli
targetedtreat
strategi
singl
prr
experiment
anim
model
human
clinic
studi
support
crucial
role
tlr
infecti
diseas
first
evid
came
observ
defect
mice
hyporespons
lp
suscept
otherwis
nonleth
infect
escherichia
coli
salmonella
typhimurium
subsequ
studi
mice
knockout
tlr
tlr
adaptor
molecul
demonstr
import
tlr
pathway
host
defens
exampl
knockout
mice
highli
suscept
infect
staphylococcu
aureu
streptococcu
pneumonia
recent
human
associ
studi
link
polymorph
affect
tlr
express
tlr
structur
augment
propens
develop
infect
discoveri
tlr
involv
innat
immun
respons
attract
much
interest
develop
drug
control
infect
improv
sepsi
manag
field
research
dynam
numer
compound
focus
tlr
test
anim
human
subject
tlr
agonist
power
adjuv
constitut
heart
vaccin
efficaci
enhanc
moreov
promis
tlrdirect
agent
develop
autoimmun
diseas
cancer
two
particular
aspect
tlrtarget
field
address
review
herein
review
popular
agonist
antagonist
agent
use
preclin
clinic
model
acut
chronic
infect
includ
sepsi
relev
regist
clinic
list
tabl
strategi
inhibit
lpsmediat
toxic
effect
initi
year
discoveri
unravel
crystal
structur
complex
lipid
toxic
moieti
lp
highli
conserv
among
endotoxin
constitut
ideal
therapeut
target
develop
eisai
research
institut
boston
andov
usa
firstgener
lipid
antagonist
deriv
rhodobact
capsulatu
endotoxin
confer
protect
experiment
model
endotoxemia
lethal
infect
e
coli
protect
effect
like
occur
bind
complex
inhibit
interact
lp
also
block
endotoxin
respons
human
healthi
volunt
challeng
intraven
lp
develop
went
phase
clinic
trial
stop
due
issu
bioavail
secondgener
lp
antagonist
drug
candid
develop
eisai
eritoran
tetrasodium
known
eritoran
synthet
lipid
analog
rhodobact
sphaeroid
eritoran
block
lpsinduc
cytokin
vitro
experiment
anim
model
phase
clinic
trial
enrol
healthi
volunt
challeng
lp
eritoran
inhibit
proinflammatori
cytokin
product
diminish
clinic
symptom
sepsi
includ
fever
chill
tachycardia
headach
addit
creactiv
protein
level
white
blood
count
significantli
decreas
advers
event
observ
dosedepend
phlebiti
due
fact
high
dose
eritoran
use
achiev
stabl
activ
drug
time
phase
random
control
trial
recruit
critic
ill
septic
patient
assess
acut
physiolog
chronic
health
evalu
ii
apach
ii
score
disclos
trend
toward
decreas
mortal
eritoran
treat
group
phase
access
control
comparison
eritoran
placebo
patient
sever
sepsi
clinic
trial
sever
sepsi
start
result
publish
patient
treat
eritoran
patient
placebo
within
h
onset
first
organ
dysfunct
unfortun
analys
reveal
reduc
allcaus
mortal
primari
secondari
endpoint
ie
day
year
mortal
eisai
tokyo
japan
waiv
submit
eritoran
market
author
treatment
sever
sepsi
januari
base
preliminari
result
access
trial
sever
reason
may
account
lack
efficaci
eritoran
instanc
patient
enrol
monitor
base
circul
level
lp
question
appropri
inclus
criteria
also
possibl
eritoran
would
effici
administr
rapidli
septic
shock
underway
point
earli
aggress
sepsi
manag
possibl
interf
factor
factor
take
account
includ
heterogen
patient
genet
background
underli
diseas
inflammatori
immun
statu
sepsi
sever
infecti
agent
site
infect
mention
earlier
intracellular
lp
sens
manner
sensit
mice
endotox
shock
noncanon
lp
detect
may
limit
efficaci
strategi
moreov
upon
infect
innat
immun
cell
like
sens
sever
mamp
via
sever
tlr
nontlr
prr
exampl
gramneg
bacteria
express
mamp
may
trigger
redund
inflammatori
pathway
lipopeptid
lp
flagellin
ssrna
bacteri
dna
observ
suggest
block
one
singl
pathway
may
insuffici
interfer
deleteri
cascad
event
observ
sepsi
posit
side
access
trial
failur
rethink
design
sepsi
clinic
trial
clearli
drug
like
eritoran
test
select
patient
treatment
efficaci
examin
adjust
accord
predefin
appropri
biomark
lp
blood
level
genet
polymorph
affect
pathway
rigor
approach
combin
power
omic
technolog
would
allow
select
homogen
cohort
followup
respons
treatment
mandatori
success
develop
antisepsi
drug
anoth
antisepsi
agent
exhibit
promis
therapeut
properti
ethyl
n
sulfamoyl
resatorvid
takeda
pharmaceut
compani
osaka
japan
origin
character
suppressor
nitric
oxid
cytokin
product
lpsstimul
macrophag
endotox
shock
mice
bind
cystein
intracellular
domain
therebi
inhibit
pathway
activ
lp
administ
consciou
guinea
pig
follow
lp
challeng
significantli
improv
septic
shock
symptom
decreas
system
level
increas
surviv
dosedepend
manner
also
increas
surviv
rate
improv
organ
dysfunct
coadminist
antibiot
mous
model
cecal
ligat
punctur
clp
effect
circul
bacteri
count
observ
doubleblind
random
placebocontrol
trial
initi
inclus
criteria
compris
symptom
sever
sepsi
accompani
either
shock
andor
respiratori
failur
studi
stop
prematur
due
failur
achiev
signific
decreas
system
cytokin
level
stage
analysi
phase
clinic
studi
design
never
launch
base
busi
decis
due
safeti
efficaci
concern
antibodi
direct
complex
gener
show
promis
result
sever
preclin
studi
engin
solubl
chimer
protein
compos
ntermin
central
domain
mous
amino
acid
fuse
fc
domain
human
chimer
molecul
use
gener
high
titer
antimous
rabbit
polyclon
antibodi
antibodi
power
inhibit
mapk
activ
cytokin
product
lpsstimul
cell
vitro
antibodi
also
hamper
cytokin
product
protect
mice
lethal
endotoxemia
administ
prophylact
therapeut
h
lp
prophylact
administr
antibodi
blunt
tnf
product
strikingli
increas
surviv
e
coli
sepsi
control
antibodi
group
group
even
impress
therapi
initi
much
h
onset
infect
model
e
coli
periton
infect
improv
surviv
studi
demonstr
antibodi
effici
adjunct
therapi
e
coli
sepsi
window
clinic
applic
compris
prophylact
therapeut
intervent
opportun
sever
monoclon
antibodi
produc
group
miyak
univers
tokyo
japan
report
gener
first
rat
monoclon
antibodi
specif
mous
complex
shown
inhibit
lpsinduc
activ
tnf
product
macrophag
rat
monoclon
antibodi
produc
novimmun
sa
geneva
switzerland
react
complex
inhibit
lpsinduc
cell
activ
protect
mice
lethal
endotoxemia
inject
h
lp
challeng
moreov
administr
time
surgeri
improv
outcom
mice
colon
ascenden
stent
periton
model
polymicrobi
abdomin
sepsi
final
rat
monoclon
antibodi
recogn
mous
human
complex
confer
protect
model
e
coli
sepsi
salmonella
enterica
sepsi
although
inhibitor
enter
clinic
preclin
trial
other
remain
development
stage
lpstrapfc
antibodi
compris
extracellular
domain
mous
fuse
link
human
igg
fc
dosedepend
decreas
releas
macrophag
opson
gramneg
bacteria
enhanc
phagocytosi
complementmedi
bacteri
kill
cellpenetr
peptid
compris
transloc
segment
drosophila
antennapedia
homeodomain
fuse
bb
loop
sequenc
ie
peptid
inhibit
lpsinduc
mapk
activ
cytokin
product
studi
requir
advanc
product
toward
clinic
level
altogeth
experiment
data
report
provid
strong
support
concept
therapi
gramneg
sepsi
gloomi
context
follow
withdrawn
rhapc
eritoran
sepsi
field
hope
enter
clinic
develop
monoclon
antibodi
produc
novimmun
abl
block
dimer
signal
trigger
lp
endogen
chemic
ligand
data
preclin
studi
model
arthriti
respiratori
inflamm
organ
injuri
highlight
potenti
favor
action
phase
clinic
studi
current
recruit
particip
evalu
drug
safeti
toler
healthi
volunt
ex
vivo
vivo
lp
challeng
pharmacokinet
pharmacodynam
also
assess
result
studi
eagerli
await
albeit
less
well
character
implic
sens
nonbacteri
microorgan
virus
fungi
recogn
olink
mannan
candida
albican
human
studi
link
polymorph
suscept
bloodstream
candidiasi
pulmonari
aspergillosi
model
dissemin
infect
c
albican
mice
exhibit
increas
fungal
load
kidney
associ
reduc
product
chemokin
kc
impair
recruit
neutrophil
treatment
hta
antihuman
mous
monoclon
antibodi
interf
neutrophilmedi
protect
c
albican
invas
cell
injuri
vitro
epitheli
model
oral
candidiasi
inhibit
tnf
product
human
pbmc
stimul
aspergillu
hypha
still
unclear
whether
target
may
benefici
context
fungal
infect
clear
yet
unexpect
pictur
arisen
viral
infect
studi
reactiv
oxygen
speci
ro
produc
nadph
oxidas
gener
oxid
host
phospholipid
stimul
product
cytokin
involv
acut
lung
injuri
use
mous
model
lethal
infect
influenza
group
stephani
vogel
univers
maryland
baltimor
usa
report
eritoran
significantli
increas
surviv
dosedepend
manner
even
administ
day
viral
challeng
lung
patholog
clinic
symptom
improv
viral
titer
influenzainduc
cytokin
gene
express
lung
homogen
decreas
compar
placebotr
group
data
suggest
therapeut
effect
eritoran
practic
time
sever
sepsi
treatment
remain
substanti
also
suggest
despit
failur
eritoran
access
trial
new
therapeut
potenti
might
still
emerg
agent
neutral
mous
monoclon
antibodi
block
lipopeptid
stimul
nuclear
transloc
mapk
phosphoryl
vitro
model
toxic
shock
microbi
challeng
high
inoculum
heatinactiv
bacillu
subtili
prevent
lethal
shocklik
syndrom
increas
surviv
administ
h
h
infect
furthermor
use
combin
antibodi
antimicrobi
therapi
protect
mice
sepsi
caus
enterica
e
coli
intracellular
antibodi
ie
intrabodi
design
block
intracellular
transloc
tlr
endoplasmat
reticulum
cell
surfac
function
scfv
intrabodi
compris
variabl
domain
heavi
light
chain
link
togeth
synthet
amino
acid
sequenc
bound
intracellularli
led
retent
accumul
insid
endoplasmat
reticulum
adenovirusmedi
express
raw
macrophag
mous
bone
marrow
deriv
macrophag
inhibit
surfac
express
tnf
product
data
suggest
therapeut
potenti
microbi
infect
mani
studi
attempt
elucid
pathogenesi
acut
kidney
injuri
associ
sepsi
involv
mechan
similar
occur
ischemiareperfus
damp
releas
infect
detect
immun
cell
recruit
ischem
tissu
andor
cell
ischem
tissu
amplifi
inflammatori
respons
induc
injuri
upon
reperfus
block
condit
may
cytoprotect
human
monoclon
antibodi
deriv
develop
opsona
therapeut
dublin
ireland
reduc
proinflammatori
cytokin
product
block
mediat
signal
porcin
model
myocardi
ischemiareperfus
injuri
pretreat
administr
h
ischemia
associ
decreas
infarct
size
result
first
human
phase
trial
evalu
safeti
toler
pharmacokinet
pharmacodynam
ascend
dose
given
intraven
healthi
adult
subject
releas
occup
inhibit
secret
induc
heatkil
listeria
monocytogen
assess
whole
blood
collect
day
treatment
either
antibodi
placebo
well
toler
signific
toxic
even
highest
dose
test
impress
dose
mgkg
occupi
molecul
express
monocyt
collect
day
challeng
respect
releas
inhibit
parallel
manner
result
suggest
treatment
could
provid
shortterm
protect
ischemiareperfus
adjust
confer
longlast
blockag
case
chronic
diseas
phase
trial
assess
safeti
toler
efficaci
kidney
transplant
patient
initi
new
techniqu
continu
implement
facilit
identif
therapeut
target
adjunct
treatment
sepsi
immunoprecipit
systemat
evolut
ligand
exponenti
enrich
selex
develop
screen
identifi
highaffin
dna
rna
molecul
bind
could
use
detect
molecul
influenc
tlrdriven
activ
promis
candid
shown
interact
therebi
obstruct
ligand
bind
receptor
inhibit
activ
product
hek
cell
cellpenetr
peptid
gener
shown
interfer
activ
mapk
cytokin
product
whether
compound
undergo
clinic
evalu
unknown
dsrna
synthet
analog
polyinosin
polycytidyl
acid
poli
c
potent
immunostimul
clinic
develop
poli
c
stabil
polylysin
carboxymethylcellulos
polyiclc
hiltonol
oncovir
washington
dc
usa
use
gener
poli
rintatolimod
tradenam
ampligen
hemispherx
biopharma
philadelphia
pa
usa
substitut
uridyl
acid
molar
ratio
synthesi
polycytidyl
acid
strand
poli
c
deriv
test
sever
clinic
trial
adjuv
vaccin
infecti
diseas
cancer
complement
haart
highli
activ
antiretrovir
therapi
human
immunodefici
viru
hiv
infect
patient
topic
discuss
poli
highli
specif
unlik
parent
molecul
poli
c
requir
melanoma
differentiationassoci
protein
cytosol
prr
virus
induct
signal
cascad
lead
type
ifn
product
poli
antivir
activ
hiv
hepat
b
viru
hbv
coxsacki
viru
sever
flavivirus
result
anim
model
lethal
respiratori
viral
infect
sever
acut
respiratori
syndrom
coronaviru
sarscov
punta
toro
viru
highlight
favor
impact
intranas
treatment
poli
c
poli
surviv
viral
load
infect
mice
mode
action
poli
c
respiratori
tract
link
induct
caspasemedi
apoptosi
ro
involv
cleavag
shed
solubl
tnf
receptor
block
tnf
bioactiv
interestingli
poli
c
protect
bacteri
infect
respiratori
tract
well
central
nervou
system
cn
mous
model
pseudomona
aeruginosa
pneumonia
secondari
clp
intranas
administr
poli
c
improv
immun
activ
lower
bacteri
load
lung
compar
untreat
anim
corrobor
result
show
enhanc
phagocytosi
kill
e
coli
microgli
cell
suggest
activ
crucial
immun
respons
cn
invad
pathogen
data
support
develop
agonist
adjuv
therapi
prevent
reduc
sever
respiratori
tract
infect
caus
virus
possibl
bacteria
connect
particular
field
phase
safeti
toler
pharmacokinet
trial
nasal
appli
polyiclc
human
volunt
ongo
explor
immun
activ
marker
phase
clinic
trial
assess
immunogen
safeti
live
attenu
influenza
vaccin
medimmun
gaithersburg
md
usa
intranas
influenza
vaccin
administ
without
poli
recent
antagonist
develop
take
consider
overactiv
viral
dsrna
may
detriment
consequ
situat
inde
report
administr
poli
c
mice
prior
intratrach
challeng
pneumonia
impair
bacteri
clearanc
increas
mortal
excess
product
type
ifn
involv
phenomenon
singlestrand
dna
oligonucleotid
ssdna
odn
effici
compet
dsrna
bind
thu
inhibit
cytokin
product
costimulatori
molecul
express
epitheli
cell
pbmc
dendrit
cell
efficaci
ssdna
odn
demonstr
cynomolgu
macaqu
intranas
inject
ssdna
odn
inhibit
poli
c
induc
cytokin
product
nasal
secret
addit
microbi
ligand
sens
damp
releas
injur
tissu
inflamm
exampl
rna
necrot
cell
promot
excess
inflammatori
respons
interestingli
administr
neutral
antibodi
mice
reduc
cecal
damag
induc
gut
ischemia
improv
surviv
anim
polymicrobi
sepsi
antibodi
given
h
clp
surgeri
collect
data
demonstr
work
endogen
sensor
necrosi
regul
immun
respons
point
receptor
modul
possibl
adjuv
therapi
sepsi
work
remain
done
clearli
delin
precis
role
viral
bacteri
infect
apprais
benefit
afford
agonist
antagonist
strategi
infecti
diseas
especi
septic
shock
singl
agonist
clinic
develop
name
flagellin
ligand
describ
date
detail
structur
basi
flagellin
recognit
obtain
crystallograph
analys
unravel
uniqu
mode
interact
two
molecul
depict
stoichiometri
ligand
arrang
bind
interfac
role
structur
constraint
induct
signal
cascad
downstream
support
structureguid
mutagenesi
delet
analys
entolimob
therapeut
agent
deriv
enterica
flagellin
implement
cleveland
biolab
buffalo
ny
usa
current
test
phase
trial
late
stage
cancer
patient
sever
clinic
trial
investig
safeti
adjuv
efficaci
recombin
flagellin
number
vaccin
set
influenza
viru
helicobact
pylori
campylobact
yersinia
pesti
west
nile
viru
etc
play
protect
role
radiationinduc
tissu
injuri
probabl
suppress
apoptosi
attenu
ro
gener
promot
tissu
regener
properti
could
explain
benefici
effect
agonist
murin
model
acut
ischem
renal
failur
administ
min
reperfus
highlight
favor
role
flagellin
tissu
damag
result
two
mous
studi
suggest
protect
repair
intestin
mucosa
serv
first
line
defens
barrier
key
mode
action
flagellin
first
studi
flagellin
shown
induc
express
ctype
lectin
bactericid
activ
restrict
small
intestin
colon
vancomycinresist
enterococcu
vre
anim
inocul
vre
via
oral
gavag
second
studi
treatment
flagellin
reduc
intestin
epithelium
destruct
induc
dextran
sodium
sulfat
chemic
use
induc
sever
acut
coliti
increas
surviv
mice
inocul
typhimurium
oral
gavag
data
suggest
flagellin
agonist
may
repres
attract
tool
treat
patholog
injur
intestin
tract
includ
sever
sepsi
antagonist
report
tolllik
receptor
agonist
test
clinic
trial
synthet
cpg
oligodeoxynucleotid
cpg
odn
among
cpg
mimic
unmethyl
cpg
dinucleotiderich
sequenc
enrich
microbi
dna
cpg
odn
power
immunostimul
exploit
adjuv
properti
vaccin
infecti
diseas
flu
malaria
hiv
infect
pneumococc
meningococc
diseas
cancer
melanoma
leukemia
glioblastoma
colorect
prostat
breast
cancer
adjuv
properti
cpg
odn
use
enhanc
phagocytosi
kill
bacteria
typhimurium
pneumonia
phagocyt
cell
interestingli
recent
studi
show
cpg
odn
given
h
prior
clp
surgeri
prevent
clpinduc
cardiac
dysfunct
mice
author
propos
target
could
use
approach
manag
cardiovascular
dysfunct
sever
sepsi
patient
therapeut
strategi
focus
immunomodul
current
implement
chronic
viral
infect
chronic
hepat
c
hcv
plasmacytoid
dendrit
cell
main
cell
produc
type
ifn
therefor
consid
play
import
role
viral
infect
agonist
stimul
plasmacytoid
dendrit
cell
produc
larg
amount
type
ifn
especi
backbon
therapi
hcv
inde
power
inhibit
viral
replic
promot
innat
adapt
host
immun
respons
moreov
ifn
product
appear
impair
plasmacytoid
dendrit
cell
hcv
patient
origin
develop
trade
name
actilon
coley
pharmaceut
wellesley
usa
compani
recent
incorpor
pfizer
new
york
citi
ny
usa
undergon
two
phase
studi
promis
result
phase
studi
drug
safeti
pharmacokinet
conduct
healthi
volunt
reveal
well
toler
immunostimulatori
effect
without
seriou
advers
event
even
use
high
dose
also
test
hcv
patient
infect
genotyp
hcv
administ
subcutan
four
random
group
differ
dose
twice
per
week
week
alon
combin
pegyl
ribavirin
agonist
effect
associ
induct
decreas
viral
load
seriou
advers
event
urticaria
pruriti
without
manifest
respiratori
complic
phase
studi
enrol
nonrespond
genotyp
hcv
patient
complet
result
releas
yet
manufactur
idera
pharmaceut
cambridg
usa
undergon
two
phase
trial
one
dose
estim
one
safeti
pharmacokinet
pharmacodynam
enrol
genotyp
hcv
patient
respect
administr
dosedepend
decreas
viral
load
increas
product
antivir
cytokin
chemokin
especi
activ
nk
tcell
respons
phase
trial
plan
april
compani
postpon
initi
decis
made
base
histolog
data
nonclin
toxicolog
studi
rodent
nonhuman
preliminari
analys
suggest
evid
atyp
lymphocyt
prolifer
although
advers
event
report
human
thorough
analysi
result
pend
phase
studi
sponsor
dynavax
berkeley
ca
usa
investig
safeti
efficaci
chronic
hcv
administ
monotherapi
combin
ribavirin
chronic
infect
genotyp
hcv
patient
result
releas
indic
well
toler
safe
without
seriou
advers
event
drug
signific
antivir
activ
base
dosedepend
antivir
respons
patient
highest
dose
show
one
log
reduct
viral
load
increas
express
type
ifndepend
antivir
gene
mxb
data
comfort
result
vitro
studi
show
stimul
human
pbmc
produc
higher
level
comparison
firstgener
agonist
bacteri
dna
releas
infect
mamp
exuber
activ
may
particip
sepsi
pathophysiolog
henc
drug
inhibitor
may
therapeut
potenti
human
sepsi
proof
concept
administr
h
surgeri
singl
dose
inhibitori
cpg
odn
block
signal
protect
mice
polymicrobi
sepsi
follow
clp
hmgb
protein
essenti
trigger
nucleic
acid
receptormedi
innat
immun
respons
hmgbbind
nonimmunogenicodn
design
inhibit
hmgbmediat
patholog
nonimmunogen
odn
term
ism
odn
test
mous
model
endotoxemia
impress
mice
treat
ism
odn
surviv
h
lp
challeng
mice
control
group
die
within
h
data
argu
possibl
use
nonimmunogenicodn
therapeut
intervent
antimalari
drug
chloroquin
well
known
antiinflammatori
properti
autoimmun
diseas
rheumatoid
arthriti
system
lupu
erythematosu
chloroquin
blunt
cytokin
product
protect
mice
toxic
shock
induc
cpg
odn
lp
chloroquin
downregul
express
suggest
act
multipl
level
inhibit
inflamm
addit
administ
h
clp
elderli
mice
treat
fluid
antimicrobi
chloroquin
significantli
improv
surviv
strengthen
renal
function
protect
multipl
organ
dysfunct
result
support
clinic
evalu
chloroquin
patient
sever
sepsi
especi
present
acut
renal
failur
base
antiinflammatori
activ
inhibit
endosom
acidif
import
cell
infect
virus
chloroquin
also
test
multipl
trial
prevent
andor
treatment
viral
infect
hiv
influenza
dengu
chikungunya
yet
mode
action
chloroquin
multifactori
imiquimod
aldara
origin
develop
pharmaceut
maplewood
mn
usa
agonist
market
antivir
treatment
ie
extern
anogenit
wart
caus
human
papilloma
viru
numer
agonist
clinic
develop
like
isatoribin
resiquimod
although
therapeut
strategi
hcv
evolv
recent
year
quest
new
immunomodulatori
target
remain
mandatori
treatment
new
agent
proteas
inhibitor
appear
effici
present
issu
resist
long
run
moreov
current
protocol
therapi
provid
replenish
specif
subtyp
cytokin
howev
use
agonist
abl
induc
varieti
ifn
subtyp
possibl
provid
radic
integr
antivir
activ
final
administr
agonist
may
overcom
advers
event
caus
like
suppress
granulocyt
coloni
stimul
factor
gcsf
lead
neutropenia
inde
revers
inhibit
gcsf
product
pbmc
obtain
hcv
patient
healthi
volunt
also
restor
defect
cytokin
product
myeloid
dendrit
cell
hiv
patient
isatoribin
anadi
pharmaceut
san
diego
ca
usa
one
first
guanosin
analog
select
agonist
implement
test
human
intraven
administr
isatoribin
hcv
patient
treatment
plan
result
reduc
plasma
concentr
hcv
rna
regardless
viru
genotyp
advers
event
compris
dosedepend
joint
pain
decreas
white
blood
cell
platelet
count
insomnia
headach
develop
oral
prodrug
could
lack
detriment
effect
isatoribin
especi
gastrointestin
tract
point
new
candid
preliminari
result
studi
conduct
promis
oral
administr
present
elev
plasma
level
isatoribin
concentr
abl
reduc
hcv
rna
plasma
infect
patient
unfortun
anadi
pharmaceut
novarti
basel
switzerland
announc
discontinu
drug
develop
due
unaccept
toxic
preclin
anim
studi
subsequ
elabor
oral
prodrug
isatoribin
anadi
pharmaceut
led
gener
exhibit
effici
induct
endogen
type
ifn
doubleblind
placebocontrol
studi
conduct
patient
chronic
hcv
either
relaps
ifnbas
therapi
interestingli
safe
well
toler
present
grade
advers
event
moreov
dosedepend
decreas
hcv
rna
level
anoth
studi
repeat
treatment
associ
transient
decreas
myeloid
plasmacytoid
dendrit
cell
increas
level
blood
patient
achiev
reduct
viral
load
suggest
impair
product
case
nonrespond
formerli
known
agonist
gener
pfizer
implement
repeat
low
dose
drug
would
accompani
benefit
agonist
activ
without
advers
event
proof
concept
studi
conduct
evalu
safeti
toler
drug
determin
pharmacokinet
pharmacodynam
twentyfour
healthi
volunt
receiv
oral
increas
dose
induc
immun
respons
dosedepend
frequencyrel
manner
howev
two
subject
exhibit
sever
lymphopenia
along
flulik
symptom
hypotens
attempt
decid
futur
perspect
compound
model
use
predict
safeti
efficaci
hcv
patient
model
exploit
clinic
result
former
studi
healthi
volunt
along
report
use
optim
requir
enter
drug
phase
studi
agonist
reach
phase
trial
demonstr
lack
efficaci
seriou
advers
effect
monocyt
hiv
patient
stimul
resiquimod
secret
augment
tnf
product
decreas
compar
control
group
addit
hiv
replic
cultur
monocyt
inhibit
promis
vitro
result
reproduc
phase
trial
enrol
patient
herp
simplex
viru
type
topic
applic
resiquimod
protect
viral
lesion
spread
howev
phase
trial
disclos
lack
efficaci
drug
although
phase
studi
treatment
hcv
demonstr
decreas
viral
load
advers
side
effect
similar
result
treatment
seriou
concern
two
phase
clinic
trial
safeti
pharmacokinet
novel
compound
gilead
scienc
foster
citi
ca
usa
current
enrol
viral
suppress
hbv
patient
respect
anoth
one
enrol
hcv
patient
recent
approv
agonist
test
origin
hbv
infect
chimpanze
drug
administr
associ
reduc
viral
load
plasma
liver
probabl
enhanc
apoptosi
hepatocyt
test
ascend
dosag
drug
healthi
volunt
present
flulik
advers
event
dose
mg
cytokin
induct
achiev
even
administr
mg
point
promis
adjunct
treatment
chronic
viral
infect
data
illustr
effort
devot
develop
agonist
treat
viral
patholog
take
account
bacteri
rna
trigger
pathway
one
may
specul
agonist
would
impact
bacteri
sepsi
unfortun
almost
data
avail
subject
one
report
intraven
inject
prior
sepsi
induct
use
colon
ascenden
stent
periton
model
increas
cytokin
releas
bacteri
clearanc
effect
surviv
report
final
consid
excess
tlr
activ
induc
virus
bacteria
may
detriment
effect
host
might
interest
gener
antagonist
counteract
overwhelm
immun
activ
condit
sever
infect
target
tlr
promis
field
sepsi
manag
infect
control
tlr
agonist
wide
use
optim
vaccin
efficaci
take
advantag
power
adjuvanc
whether
tlr
agonist
antagonist
success
treatment
therapi
especi
sepsi
establish
agonist
yield
promis
result
treat
viral
infect
studi
test
antagonist
drug
mainli
histor
reason
ligand
specif
lesser
extent
favorit
target
develop
antisepsi
drug
domain
research
monopol
import
resourc
unfortun
mani
drug
test
anim
model
enter
human
studi
proceed
like
eritoran
achiev
primari
endpoint
goal
andor
accompani
manifest
advers
event
anim
model
provid
invalu
inform
role
tlr
mechan
underli
infect
pathogenesi
lack
complex
term
comorbid
host
respons
compar
human
diseas
explor
effici
new
treatment
strategi
improv
design
clinic
studi
mandatori
discrimin
patient
could
benefit
therapi
base
genotyp
exampl
affect
tlr
pathway
express
target
molecul
select
homogen
welldescrib
popul
bear
underli
condit
diseas
sever
ideal
sepsi
studi
use
specif
biomark
help
patient
enrol
weigh
treatment
efficaci
realist
condit
failur
recent
trial
patient
sever
sepsi
taught
us
valuabl
lesson
regard
patient
select
time
intervent
followup
block
one
singl
mediat
may
also
suffici
interfer
sepsi
develop
sepsisspecif
tlrtarget
therapi
patient
path
strewn
obstacl
excit
promis
area
research
studi
offer
new
possibl
prevent
intervent
infecti
diseas
also
condit
cancer
allergi
asthma
autoimmun
diseas
either
directli
improv
vaccin
author
declar
research
conduct
absenc
commerci
financi
relationship
could
constru
potenti
conflict
interest
